# Newish

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/newish

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.newishes.com
- Total disclosed funding: $15M
- Latest round: Series B (Jun 12, 2026)
- Investors on record: 7

## About

Based in Beijing, China and founded in 2014, Newish Technology (Beijing) Co., Ltd., dba Newish, is a biotech company that focuses on developing antitumor DNA vaccine drugs. The company has a GMP new drug pilot plant, a new nucleic acid drug, and a tumor metabolism drug research and development laboratory in the Beijing Economic and Technological Development Zone. The company has acquired more than 40 patents. The company has acquired the Excellent Enterprise Award. In June 2026, Newish closed CNY 100 million in Series B funding led by Shanghai Kangcheng Investment Management, with participation from New Frontier, Zhiyue Investment Management, Qian Yuan Feng Qiong, and other investors.

The company has built two in-house technology platforms, including STARi (Super Targeting Activated Response of immunization) platform and the Newish T-cell therapeutic platform. The STARi platform is an ultra-targeted nucleic acid drug platform that activates T-cell immune responses for the development of various tumor vaccine products.

The company generates revenue by developing pharmacies.

## Funding rounds

- Series B, Jun 12, 2026, $15M — New Frontier, Zhiyue Investment Management, Shanghai Kangcheng Investment Management
- Series B, Jul 24, 2025 — Jinkong Qiyuan Capital, Beijing Excellence Meijia Medical Investment Management Co., Ltd., Broadcom Capital
- Series A, Sep 8, 2021 — Digital China Capital

## Investors

- Digital China Capital (https://capitalatlas.ai/funds/digital-china-capital) — Series A
- Jinkong Qiyuan Capital (https://capitalatlas.ai/funds/jinkong-qiyuan-capital) — Series B
- Beijing Excellence Meijia Medical Investment Management Co., Ltd. — Series B
- Broadcom Capital — Series B
- New Frontier (https://capitalatlas.ai/funds/new-frontier) — Series B
- Zhiyue Investment Management (https://capitalatlas.ai/funds/zhiyue-investment-management) — Series B
- Shanghai Kangcheng Investment Management — Series B